Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 (HHLA2) Antibody by the U.S. FDA

HBM1020 is the globally first-in-class fully human monoclonal antibody targeting B7H7. HBM1020 is also the globally first-ever monoclonal antibody targeti...

Harbour BioMed Reports the Latest Progress from Phase I Clinical Trial of Porustobart in Combination with Toripalimab in Advanced Melanoma

Cambridge, MA, Rotterdam, NL, Suzhou, CN— December 8, 2022   Harbour BioMed (the “Company”, HKEX: 02142), today announced the pro...

Invitation | Harbour BioMed Investor Day 2022

Harbour BioMed to Present the Latest Progress of Next-Generation Fully Human Heavy-chain Antibody Porustobart with Unique Treg Depletion Mechanism at ESMO I-O 2022

 Cambridge, MA, Rotterdam, NL, Suzhou, CN— Nov 25, 2022   Harbour BioMed (the “Company”, HKEX: 02142), today announced that ...

Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics

CAMBRIDGE, MA— November 21, 2022   Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution...

Harbour BioMed Launches Nona Biosciences’ “Ideas to IND” Preclinical Solutions Business to Accelerate Global Biotherapeutic Innovation

Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2022   Harbor BioMed (HKEX: 02142) today announced establishment of a wholly-owned sub...

Harbour BioMed Enters into a License and Collaboration Agreement with Moderna

Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 11, 2022   Harbour BioMed (the “Company”, HKEX: 02142) today announced that N...

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody in the United States

Cambridge, MA, Rotterdam, NL, Suzhou, CN— October 20, 2022   Harbour BioMed (“HBM”, HKEX: 02142) announced that, it has successful...

Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

Cambridge, MA, Rotterdam, NL, Suzhou, CN — October 13, 2022   Harbour BioMed (the “Company”, HKEX: 02142), a global biopharmaceuti...

Harbour BioMed Enters into Agreement with CSPC Pharmaceutical Group Limited for Batoclimab (HBM9161) in Greater China

Cambridge, MA, Rotterdam, NL, Suzhou, CN - October 10, 2022   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical com...